Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement

被引:5
|
作者
Zhang, Wen [1 ]
Xu, Qingwen [1 ]
Peng, Jing [1 ]
Zhang, Xiaotong [1 ]
Chen, Lu [1 ]
Wu, Yilai [1 ]
Yang, Kui [1 ]
Luan, Jiajie [1 ]
Liu, Xiaoyun [1 ]
机构
[1] Yijishan Hosp, Affiliated Hosp 1, Wannan Med Coll, Yijishan Hosp, Wuhu, Anhui, Peoples R China
关键词
national centralized drug procurement; medical institutions; problems; challenge; China;
D O I
10.3389/fphar.2023.1233491
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement was investigated and analyzed in order to provide reference for the regulatory agencies to formulate policies.Methods: A questionnaire survey was conducted to collect the problems encountered by 329 Chinese medical institutions in implementing the national centralized drug procurement and the corresponding suggestions provided by relevant experts. Statistical analysis was performed to identify differences in the themes and the number of collected problems, further revealing the relevance to the region in which the medical institutions is located.Result: 1360 problems and suggestions were collected from 329 Chinese medical institutions that located in North (19.15%), Northeast (5.78%), East (33.43%), Central (10.03%), South (9.73%), Southwest (14.89%), and Northwest China (6.99%). There was statistically significant difference in the number of collected problems and suggestions between regions (p < 0.001). Furthermore, the content of gathered problems and suggestions involves in 15 themes including system construction, organizational system and work responsibilities, reasonable measurement and reporting of procurement volume et al. These themes that these medical institutions are focusing on are mainly centered on the supply guarantee (15%), reasonable measurement and reporting of procurement volume (11.40%) and guarantee measures for clinical priority use (9.48%) of drugs with national centralized procurement. Meanwhile, we found that problems regarding the supply guarantee of drugs with national centralized procurement displayed significant difference between regions (p = 0.0096).Conclusion: Chinese medical institutions are facing great challenges in implementing the national centralized drug procurement. The scientific study and judgment of the current situation and the construction of corresponding solution require a precise classification of the problems encountered by medical institutions in the process of implementing the national centralized drug procurement policy, which is of great practical significance for deepening the reform of the medical and health system.
引用
收藏
页数:7
相关论文
共 30 条
  • [21] Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China
    Li, Jiaming
    Zhang, Xinyue
    Wang, Rui
    Cao, Keyao
    Wan, Luhui
    Ren, Xu
    Ding, Jinxi
    Li, Wei
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [22] The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: A difference-in-differences analysis in a large tertiary hospital in China
    Zhang, Yuan-jin
    Ren, Yan
    Zheng, Quan
    Tan, Jing
    Yao, Ming-hong
    Huang, Yun-xiang
    Zhang, Xia
    Zou, Kang
    Zhao, Shao-yang
    Sun, Xin
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [23] Impacts of Chinese national centralized volume-based procurement policy targeting meropenem on prescription of designated antimicrobials for inpatients: an interrupted time series analysis
    Lin, Zhi-Hang
    Wang, Can-Ming
    Cai, Li-Li
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [24] Practical Challenges in Implementing Human Rights Treaties in National Law: Problems of Finding and Translating Relevant International Norms
    Sirin, Tolga
    Orcan, Necdet Umut
    ISTANBUL HUKUK MECMUASI, 2022, 80 (01): : 273 - 297
  • [25] The Change of Original- and Generic-Targeted Antitumor Drugs under the National Centralized Drug Procurement Policy in Hohhot: An Interrupted Time-Series Analysis
    Wu, Rihan
    Gong, Zhaotang
    Wang, Weisong
    Zhu, Benben
    Guleng, Siri
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2024, 2024
  • [26] Implementing Pharmacogenomics in Clinical Practice: Challenges and Realities to Managing Gene-drug Pair Information in the Electronic Medical Record
    Waring, Stephen C.
    Friday, Bret E.
    Sperl, David J.
    Witten, Dianne L.
    Schillo, Paul J.
    Rivers, Zachary T.
    Brown, Jacob T.
    Stenehjem, David D.
    GENETIC EPIDEMIOLOGY, 2019, 43 (07) : 916 - 917
  • [27] Impact of the National Centralized Drug Procurement Policy (4+7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series
    Lan, Tianwei
    Guan, Liying
    Pang, Xinyue
    Li, Xin
    Yu, Qian
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (01) : 104 - 111
  • [28] Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients
    Shang, Lili
    Cheng, Yan
    Zhou, Jifang
    Bao, Yuqing
    Kong, Desong
    Huang, Ruijian
    Chen, Yanfei
    Wang, Hao
    Gu, Ning
    Ma, Aixia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Medical Burden of Disease Among Individuals in Recovery From Alcohol and Other Drug Problems in the United States: Findings From the National Recovery Survey
    Eddie, David
    Greene, M. Claire
    White, William L.
    Kelly, John F.
    JOURNAL OF ADDICTION MEDICINE, 2019, 13 (05) : 385 - 395
  • [30] THE 1985 DENT MEMORIAL LECTURE - I NEED HEROIN - 30 YEARS EXPERIENCE OF DRUG-DEPENDENCE AND OF THE MEDICAL CHALLENGES AT LOCAL, NATIONAL, INTERNATIONAL AND POLITICAL LEVEL - WHAT NEXT
    CONNELL, PH
    BRITISH JOURNAL OF ADDICTION, 1986, 81 (04): : 461 - 472